Papillary Renal Cell Carcinoma — Variants & evidence

Papillary Renal Cell Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

5 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR2 Overexpression1
(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID6454 Only 12/118(10.2%) of patients with type I papillary renal cell carcinoma expressed FGFR2 whereas 37/96 (38.5%) patients with type II papillary renal cell carcinoma(P=0.001). In addition, FGFR2 expre… (full text at CIViC) PMID 27379982 · Tsimafeyeu et al., 2017 · Open in CIViC	civic
FH Deficient1
Bevacizumab + ErlotinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID12940 In the open‑label phase II AVATAR trial (NCT01130519), patients with sporadic papillary RCC (n = 40) received erlotinib plus bevacizumab, with ORR as the primary endpoint. They demonstrated a lower OR… (full text at CIViC) PMID 40532152 · Srinivasan et al., 2025 · Open in CIViC	civic
FLCN Mutation1
Everolimus	Predictive	C	Supports Sensitivity Response	3	submitted	EID5990 In a patient with Birt-Hogg-Dubé syndrome-associated papillary renal cell carcinoma use of everolimus as sixth-line systematic treatment exhibited a relatively long-term effect as compared with the pr… (full text at CIViC) PMID 23995526 · Nakamura et al., 2013 · Open in CIViC	civic
MET Mutation1
Foretinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID796 In a retrospective analysis of 74 patients with papillary renal cell carcinoma, treated with foretinib, MET germline mutation was associated with improved response rate. A response was observed in 5 … (full text at CIViC) PMID 23213094 · Choueiri et al., 2013 · Open in CIViC	civic
ZHX2 Overexpression1
Sorafenib	Predictive	C	Supports Sensitivity Response	3	submitted	EID9114 Efficacy of second-line sorafenib treatment (initially 12.5 mg/day, escalated to 25 mg/day) in a 82-year old male patient with type 2 papillary renal cell carcinoma was confirmed with a partial respon… (full text at CIViC) PMID 32743370 · Morinaga et al., 2019 · Open in CIViC	civic

Data updated 22 minutes agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.